title: Benefits of progestin contraception in non-allergic angioedema.
abstract: BACKGROUND
  Hereditary angioedema attacks can be induced or worsened by oral contraceptive containing oestrogens.
  
  
  OBJECTIVE
  The purpose of this study was to assess the impact of progestin contraceptives on angioedema attacks.
  
  
  METHODS
  We conducted a French retrospective, multi-centre study of progestin contraception in women with non-allergic angioedema, including hereditary angioedema type I, II and III and idiopathic angioedema. Patients were classified into four groups according to frequency of attacks. We evaluated the effects of progestin on the mean number of attacks and compared the number of patients in each group before and under progestin contraception. The influence of hormonal factors on the course of angioedema was also assessed.
  
  
  RESULTS
  Fifty-five women were included: mean age was 32.1 years (16-52) and mean follow-up 32.4 months (SD:29). Fourteen women were classified as type I (25.4%), two as type II (3.6%) and 19 as type III (34%) and 20 were idiopathic (36%). Seventeen patients were taking a low dose progestin-only pill (POP), 24 antigonadotropic progestins (AGP) and 14 both successively. Total or partial improvement was observed in 81.8% (45/55) of the patients and more frequently in those on an AGP agent (34 patients, 89.5%) than on POP (19 patients, 61.3%) (P = 0.013).
  
  
  CONCLUSIONS
  This is the first study evaluating the interest of antigonadotropic progestin contraception in a series of women with non-allergic angioedema. Progestins, especially antigonadotropic progestins, appear to convey a marked benefit in most cases. Antigonadotropic progestins could thus be recommended as adjuvant treatment in childbearing women with non-allergic angioedema.
authors.affiliation: Gynaecological Endocrinology Unit, Paris Descartes University, Port Royal Cochin, APHP, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Saule
authors.forename: I
authors.initials: I
authors.lastname: Boccon-Gibod
authors.forename: O
authors.initials: O
authors.lastname: Fain
authors.forename: G
authors.initials: G
authors.lastname: Kanny
authors.forename: G
authors.initials: G
authors.lastname: Plu-Bureau
authors.forename: L
authors.initials: L
authors.lastname: Martin
authors.forename: D
authors.initials: D
authors.lastname: Launay
authors.forename: L
authors.initials: L
authors.lastname: Bouillet
authors.forename: A
authors.initials: A
authors.lastname: Gompel
mesh_terms: D000293:Adolescent; D000328:Adult; D054179:Angioedemas, Hereditary / Q000188:drug therapy* / Q000378:metabolism; D003270:Contraceptive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003277:Contraceptives, Oral, Combined; D005260:Female; D006801:Humans; D008875:Middle Aged; D011247:Pregnancy; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011627:Puberty / Q000378:metabolism; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003270:Contraceptive Agents; D003277:Contraceptives, Oral, Combined; D011372:Progestins